BlogFile: Dendreon Corporation (DNDN)

BioHealth Investor.com



COMPANY BlogFILE
updated: May 15, 2007


DENDREON CORPORATION

3005 First Avenue
Seattle, WA 98121
Phone: (206) 256-4545
Fax: (206) 256-0571
www.dendreon.com

Investor/Public Relations
(206) 829-1500
ir@dendreon.com



COMPANY DESCRIPTION

Dendreon Corporation is a Seattle-based biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Through innovative science and technology, is striving to develop and commercialize products that address unmet medical needs, improve survival and have a favorable safety profile.



BUSINESS INFORMATION

Public company
Ticker: DNDN
Market: NASDAQ
Industry: Biotechnology



LATEST BLOG COMMENTARY

Dendreon, the Day That Could Have Been and What to Expect Now
24/7 Wall St.
May 15, 2007

Why Did the FDA Decide to Flunk Dendreon's Provenge?
SeekingAlpha
May 14, 2007

Dendreon - Is Provenge Snake Oil or Cure?
The Disciplined Investor
May 12, 2007

DNDN… is it Over?
Echo To All
May 12, 2007

Rantasorous Rx
Health Business Blog
May 11, 2007

Comments From Dendreon's Conference Call (May 10, 2007)
24/7 Wall St.
May 10, 2007

Dendreon Gets Complete Response Letter
Eye On FDA
May 09, 2007

Dendreon Nailed by FDA
24/7 Wall St.
May 09, 2007

Dendreon: The Short Story
SeekingAlpha
May 09, 2007

Dendreon: The Next Genentech/Amgen?
SeekingAlpha
May 04, 2007



Source: BioHealth Investor.com

____________________